Gabriel Filippi

Gabriel Filippi is a Portuguese patient advocate and researcher who has become a leading voice in exposing the long-term neurological and metabolic harms caused by the antipsychotic medication Zyprexa (olanzapine). After being prescribed Zyprexa for just one month in 1998 at the age of 20, he suffered irreversible damage, including rapid weight gain (over 60kg), the development of type 2 diabetes, and what he describes as a "chemical lobotomy"—a permanent loss of his brain's ability to respond to any psychoactive substance, robbing him of joy, emotional connection, and transcendence.

His work centers on a powerful, patient-led investigation into the mechanisms of this injury. He has meticulously documented his experience, self-experimented with substances like methylphenidate (which temporarily restored function, proving the damage is functional, not degenerative), and compiled a robust body of scientific evidence from peer-reviewed studies. His research highlights how Zyprexa causes receptor downregulation (D2, 5-HT2A), epigenetic silencing, and hypothalamic damage, leading to a "silent epidemic" of harm affecting an estimated 25 million people.

Filippi's advocacy is a multi-pronged mission for justice: he has filed a formal complaint with Portugal's medicines agency (INFARMED), launched a GoFundMe campaign to finance PET scans and legal action, and created the website "Surviving Zyprexa" to educate others. He is actively seeking collaborations with research institutions like the Medical University of Vienna and the Champalimaud Foundation to scientifically validate his findings. His work aims to force regulatory agencies like the EMA to add a black box warning for permanent neurological damage and to pioneer recovery protocols using treatments like betahistine, liraglutide, and ketamine.